TBIO — Telesis Bio Income Statement
0.000.00%
Last trade - 00:00- $1.60m
- $3.50m
- $27.51m
Annual income statement for Telesis Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4.8 | 6.58 | 11 | 27.4 | 27.5 |
| Cost of Revenue | |||||
| Gross Profit | 2.13 | 3.63 | 4.3 | 15.6 | 16.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 11.8 | 22.9 | 47 | 74.6 | 74 |
| Operating Profit | -6.98 | -16.4 | -36 | -47.2 | -46.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.3 | -18 | -38.9 | -48.4 | -47.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.3 | -18 | -39 | -48.5 | -47.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.3 | -18 | -39 | -48.5 | -47.7 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.3 | -18 | -39 | -48.5 | -49 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.11 | -11.1 | -38.1 | -29.3 | -25.1 |
| Dividends per Share |